studies

metastatic (mCRPC) - 1st line (L1), ipilimumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCA184-043, 2014 0.85 [0.72; 1.00] CA184-095, 2017 1.11 [0.88; 1.40] 0.96[0.74; 1.24]CA184-043, 2014, CA184-095, 2017271%1,401lownot evaluable progression or deaths (PFS)detailed resultsCA184-043, 2014 0.70 [0.60; 0.81] CA184-095, 2017 0.67 [0.55; 0.81] 0.69[0.61; 0.77]CA184-043, 2014, CA184-095, 201720%1,401lownot evaluable AE (any grade)detailed resultsCA184-043, 2014 4.23 [1.92; 9.30] CA184-095, 2017 1.98 [1.00; 3.93] 2.82[1.34; 5.93]CA184-043, 2014, CA184-095, 2017251%1,387lownot evaluable AE (grade 3-4)detailed resultsCA184-043, 2014 2.08 [1.57; 2.76] CA184-095, 2017 11.20 [5.91; 21.26] 4.71[0.91; 24.49]CA184-043, 2014, CA184-095, 2017295%1,387lownot evaluable AE leading to treatment discontinuation (any grade)detailed resultsCA184-043, 2014 2.88 [2.05; 4.06] CA184-095, 2017 4.78 [2.89; 7.94] 3.58[2.19; 5.86]CA184-043, 2014, CA184-095, 2017262%1,387lownot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsCA184-095, 2017 4.60 [2.55; 8.28] 4.60[2.55; 8.28]CA184-095, 201710%598NAnot evaluable SAE (any grade)detailed resultsCA184-095, 2017 3.15 [2.18; 4.57] 3.15[2.18; 4.57]CA184-095, 201710%598NAnot evaluable SAE (grade 3-4)detailed resultsCA184-095, 2017 2.55 [1.70; 3.82] 2.55[1.70; 3.82]CA184-095, 201710%598NAnot evaluable STRAE (grade 3-4)detailed resultsCA184-095, 2017 17.86 [6.48; 49.27] 17.86[6.48; 49.27]CA184-095, 201710%598NAnot evaluable TRAE (any grade)detailed resultsCA184-043, 2014 3.61 [2.67; 4.89] CA184-095, 2017 14.03 [6.42; 30.66] 6.77[1.80; 25.50]CA184-043, 2014, CA184-095, 2017290%1,387lownot evaluable TRAE (grade 3-4)detailed resultsCA184-043, 2014 5.04 [3.42; 7.41] 5.04[3.42; 7.41]CA184-043, 201410%789NAnot evaluable TRAE leading to death (grade 5)detailed resultsCA184-095, 2017 9.16 [0.53; 158.85] 9.16[0.53; 158.85]CA184-095, 201710%598NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCA184-043, 2014 2.88 [2.05; 4.06] 2.88[2.05; 4.06]CA184-043, 201410%789NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCA184-043, 2014 3.70 [2.43; 5.65] 3.70[2.43; 5.65]CA184-043, 201410%789NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.18; 22.37] 2.02[0.18; 22.37]CA184-043, 201410%789NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsOut of scaleCA184-043, 2014 37.97 [2.28; 632.95] 37.97[2.28; 632.95]CA184-043, 201410%789NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCA184-095, 2017 5.04 [0.27; 92.68] 5.04[0.27; 92.68]CA184-095, 201710%598NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsOut of scaleCA184-043, 2014 23.14 [7.19; 74.50] CA184-095, 2017 68.89 [4.24; 1120.59] 27.24[9.27; 80.07]CA184-043, 2014, CA184-095, 201720%1,387lownot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsCA184-043, 2014 3.05 [0.61; 15.23] 3.05[0.61; 15.23]CA184-043, 201410%789NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCA184-095, 2017 2.53 [0.55; 11.67] 2.53[0.55; 11.67]CA184-095, 201710%598NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsOut of scaleCA184-043, 2014 28.89 [9.01; 92.57] 28.89[9.01; 92.57]CA184-043, 201410%789NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed resultsCA184-043, 2014 10.19 [0.55; 187.21] 10.19[0.55; 187.21]CA184-043, 201410%789NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCA184-043, 2014 4.05 [0.18; 90.01] 4.05[0.18; 90.01]CA184-043, 201410%789NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsCA184-043, 2014 2.30 [0.70; 7.52] 2.30[0.70; 7.52]CA184-043, 201410%789NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCA184-043, 2014 2.03 [0.50; 8.18] 2.03[0.50; 8.18]CA184-043, 201410%789NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsCA184-043, 2014 0.50 [0.05; 5.57] 0.50[0.05; 5.57]CA184-043, 201410%789NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCA184-095, 2017 7.09 [0.40; 125.56] 7.09[0.40; 125.56]CA184-095, 201710%598NAnot evaluable Neurologic TRAE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] CA184-095, 2017 0.50 [0.03; 8.00] 0.87[0.10; 7.48]CA184-043, 2014, CA184-095, 201720%1,387lownot evaluable Rash TRAE (grade 3-4)detailed resultsCA184-043, 2014 4.05 [0.18; 90.01] CA184-095, 2017 10.21 [0.59; 175.63] 6.69[0.82; 54.44]CA184-043, 2014, CA184-095, 201720%1,387lownot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsCA184-043, 2014 8.13 [0.43; 154.37] 8.13[0.43; 154.37]CA184-043, 201410%789NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCA184-095, 2017 4.02 [0.21; 76.42] 4.02[0.21; 76.42]CA184-095, 201710%598NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsCA184-043, 2014 0.86 [0.29; 2.59] 0.86[0.29; 2.59]CA184-043, 201410%789NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsCA184-043, 2014 3.57 [0.74; 17.31] 3.57[0.74; 17.31]CA184-043, 201410%789NAnot evaluable Adrenal insufficiency AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.18; 22.37] 2.02[0.18; 22.37]CA184-043, 201410%789NAnot evaluable Anaemia AE (grade 3-4)detailed resultsCA184-043, 2014 0.93 [0.59; 1.47] 0.93[0.59; 1.47]CA184-043, 201410%789NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsCA184-043, 2014 0.86 [0.29; 2.59] 0.86[0.29; 2.59]CA184-043, 201410%789NAnot evaluable Asthenia AE (grade 3-4)detailed resultsCA184-043, 2014 2.09 [1.06; 4.12] 2.09[1.06; 4.12]CA184-043, 201410%789NAnot evaluable Back pain AE (grade 3-4)detailed resultsCA184-043, 2014 0.69 [0.35; 1.40] 0.69[0.35; 1.40]CA184-043, 201410%789NAnot evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed resultsCA184-043, 2014 0.83 [0.54; 1.28] 0.83[0.54; 1.28]CA184-043, 201410%789NAnot evaluable Cardiac disorders AE (grade 3-4)detailed resultsCA184-043, 2014 4.13 [1.16; 14.74] 4.13[1.16; 14.74]CA184-043, 201410%789NAnot evaluable Colitis AE (grade 3-4)detailed resultsOut of scaleCA184-043, 2014 37.97 [2.28; 632.95] 37.97[2.28; 632.95]CA184-043, 201410%789NAnot evaluable Constipation AE (grade 3-4)detailed resultsCA184-043, 2014 0.67 [0.11; 4.03] 0.67[0.11; 4.03]CA184-043, 201410%789NAnot evaluable Cough AE (grade 3-4)detailed resultsCA184-043, 2014 4.05 [0.18; 90.01] 4.05[0.18; 90.01]CA184-043, 201410%789NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsCA184-043, 2014 1.27 [0.59; 2.75] 1.27[0.59; 2.75]CA184-043, 201410%789NAnot evaluable Diabetes mellitus AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsCA184-043, 2014 10.81 [4.89; 23.91] 10.81[4.89; 23.91]CA184-043, 201410%789NAnot evaluable Dizziness AE (grade 3-4)detailed resultsCA184-043, 2014 1.01 [0.06; 16.17] 1.01[0.06; 16.17]CA184-043, 201410%789NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsCA184-043, 2014 2.67 [1.10; 6.46] 2.67[1.10; 6.46]CA184-043, 201410%789NAnot evaluable Endocrine disorders AE (grade 3-4)detailed resultsCA184-043, 2014 3.05 [0.61; 15.23] 3.05[0.61; 15.23]CA184-043, 201410%789NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsCA184-043, 2014 0.50 [0.02; 15.04] 0.50[0.02; 15.04]CA184-043, 201410%789NAnot evaluable Erythema AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Eye disorders AE (grade 3-4)detailed resultsCA184-043, 2014 0.60 [0.14; 2.53] 0.60[0.14; 2.53]CA184-043, 201410%789NAnot evaluable Fatigue AE (grade 3-4)detailed resultsCA184-043, 2014 1.17 [0.73; 1.88] 1.17[0.73; 1.88]CA184-043, 201410%789NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsCA184-043, 2014 1.01 [0.06; 16.17] 1.01[0.06; 16.17]CA184-043, 201410%789NAnot evaluable Gastritis AE (grade 3-4)detailed resultsCA184-043, 2014 8.13 [0.43; 154.37] 8.13[0.43; 154.37]CA184-043, 201410%789NAnot evaluable Gastrointestinal disorders AE (grade 3-4)detailed resultsCA184-043, 2014 3.31 [2.16; 5.08] 3.31[2.16; 5.08]CA184-043, 201410%789NAnot evaluable General disorders and administration site conditions AE (grade 3-4)detailed resultsCA184-043, 2014 1.26 [0.89; 1.79] 1.26[0.89; 1.79]CA184-043, 201410%789NAnot evaluable Headache AE (grade 3-4)detailed resultsCA184-043, 2014 1.01 [0.14; 7.19] 1.01[0.14; 7.19]CA184-043, 201410%789NAnot evaluable Hepatobiliary disorders (AE grade 3-4)detailed resultsCA184-043, 2014 7.16 [0.88; 58.50] 7.16[0.88; 58.50]CA184-043, 201410%789NAnot evaluable Hypertension AE (grade 3-4)detailed resultsCA184-043, 2014 1.01 [0.06; 16.17] 1.01[0.06; 16.17]CA184-043, 201410%789NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsCA184-043, 2014 1.01 [0.06; 16.17] 1.01[0.06; 16.17]CA184-043, 201410%789NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsCA184-043, 2014 4.05 [0.18; 90.01] 4.05[0.18; 90.01]CA184-043, 201410%789NAnot evaluable Increase AST AE (grade 3-4)detailed resultsCA184-043, 2014 14.59 [1.91; 111.51] 14.59[1.91; 111.51]CA184-043, 201410%789NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsCA184-043, 2014 3.07 [0.82; 11.43] 3.07[0.82; 11.43]CA184-043, 201410%789NAnot evaluable Infections and infestations AE (grade 3-4)detailed resultsCA184-043, 2014 2.13 [1.22; 3.71] 2.13[1.22; 3.71]CA184-043, 201410%789NAnot evaluable Injury, poisoning and procedure AE (grade 3-4)detailed resultsCA184-043, 2014 2.56 [0.80; 8.23] 2.56[0.80; 8.23]CA184-043, 201410%789NAnot evaluable Investigations AE (grade 3-4)detailed resultsCA184-043, 2014 1.82 [1.17; 2.84] 1.82[1.17; 2.84]CA184-043, 201410%789NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsCA184-043, 2014 0.33 [0.03; 3.23] 0.33[0.03; 3.23]CA184-043, 201410%789NAnot evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed resultsCA184-043, 2014 1.88 [1.18; 2.99] 1.88[1.18; 2.99]CA184-043, 201410%789NAnot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Musculoskeletal and connective tissue disorders AE (grade 3-4)detailed resultsCA184-043, 2014 0.68 [0.44; 1.04] 0.68[0.44; 1.04]CA184-043, 201410%789NAnot evaluable Myalgia AE (grade 3-4)detailed resultsCA184-043, 2014 3.04 [0.31; 29.34] 3.04[0.31; 29.34]CA184-043, 201410%789NAnot evaluable Myopathy AE (grade 3-4)detailed resultsCA184-043, 2014 0.50 [0.02; 15.04] 0.50[0.02; 15.04]CA184-043, 201410%789NAnot evaluable Nausea AE (grade 3-4)detailed resultsCA184-043, 2014 1.60 [0.61; 4.17] 1.60[0.61; 4.17]CA184-043, 201410%789NAnot evaluable Nervous system disorders AE (grade 3-4)detailed resultsCA184-043, 2014 0.83 [0.49; 1.43] 0.83[0.49; 1.43]CA184-043, 201410%789NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsCA184-043, 2014 0.17 [0.01; 3.34] 0.17[0.01; 3.34]CA184-043, 201410%789NAnot evaluable Paraesthesia AE (grade 3-4)detailed resultsCA184-043, 2014 1.01 [0.06; 16.17] 1.01[0.06; 16.17]CA184-043, 201410%789NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsCA184-043, 2014 0.50 [0.02; 15.04] 0.50[0.02; 15.04]CA184-043, 201410%789NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsCA184-043, 2014 0.25 [0.01; 5.58] 0.25[0.01; 5.58]CA184-043, 201410%789NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsCA184-043, 2014 4.13 [1.16; 14.74] 4.13[1.16; 14.74]CA184-043, 201410%789NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Proteinuria AE (grade 3-4)detailed resultsCA184-043, 2014 0.50 [0.02; 15.04] 0.50[0.02; 15.04]CA184-043, 201410%789NAnot evaluable Pruritus AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsCA184-043, 2014 5.09 [0.59; 43.77] 5.09[0.59; 43.77]CA184-043, 201410%789NAnot evaluable Rash AE (grade 3-4)detailed resultsCA184-043, 2014 4.05 [0.18; 90.01] 4.05[0.18; 90.01]CA184-043, 201410%789NAnot evaluable Renal and urinary disorders AE (grade 3-4)detailed resultsCA184-043, 2014 1.11 [0.60; 2.04] 1.11[0.60; 2.04]CA184-043, 201410%789NAnot evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed resultsCA184-043, 2014 1.68 [0.89; 3.19] 1.68[0.89; 3.19]CA184-043, 201410%789NAnot evaluable Sepsis AE (grade 3-4)detailed resultsCA184-043, 2014 1.52 [0.25; 9.12] 1.52[0.25; 9.12]CA184-043, 201410%789NAnot evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed resultsCA184-043, 2014 12.26 [0.68; 220.32] 12.26[0.68; 220.32]CA184-043, 201410%789NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsCA184-043, 2014 0.37 [0.10; 1.42] 0.37[0.10; 1.42]CA184-043, 201410%789NAnot evaluable Urticaria AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Uveitis AE (grade 3-4)detailed resultsCA184-043, 2014 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CA184-043, 201410%789NAnot evaluable Vascular disorders AE (grade 3-4)detailed resultsCA184-043, 2014 1.45 [0.55; 3.85] 1.45[0.55; 3.85]CA184-043, 201410%789NAnot evaluable Vomiting AE (grade 3-4)detailed resultsCA184-043, 2014 0.78 [0.29; 2.11] 0.78[0.29; 2.11]CA184-043, 201410%789NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsCA184-043, 2014 5.09 [0.59; 43.77] 5.09[0.59; 43.77]CA184-043, 201410%789NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-02 15:33 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 207 - treatments: 850,329,558,579,549,868

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons